Molecular glue degrader for tumor treatment DOI Creative Commons

Yuhan Hu,

Yan Yan, Jiehao Wang

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Dec. 12, 2024

Targeted Protein Degradation (TPD) represented by Proteolysis-Targeting Chimeras (PROTAC) is the frontier field in research and development of antitumor therapy, which oral drug HP518 Receives FDA Proceed Authorization for its IND Application Prostate Cancer Treatment. Recently, molecular glue, functioning via degradation target protein emerging as a promising modality therapeutic agents, while exhibits greater advantages over PROTAC, including improved efficiency, resistance-free properties, capacity to selectively “undruggable” proteins. This marks revolutionary advancement landscape small molecule drugs. Given that glue still early stage, we summarized mechanisms drugs clinical trials diverse feasible design strategies therapeutics.

Language: Английский

Molecular glue degrader for tumor treatment DOI Creative Commons

Yuhan Hu,

Yan Yan, Jiehao Wang

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Dec. 12, 2024

Targeted Protein Degradation (TPD) represented by Proteolysis-Targeting Chimeras (PROTAC) is the frontier field in research and development of antitumor therapy, which oral drug HP518 Receives FDA Proceed Authorization for its IND Application Prostate Cancer Treatment. Recently, molecular glue, functioning via degradation target protein emerging as a promising modality therapeutic agents, while exhibits greater advantages over PROTAC, including improved efficiency, resistance-free properties, capacity to selectively “undruggable” proteins. This marks revolutionary advancement landscape small molecule drugs. Given that glue still early stage, we summarized mechanisms drugs clinical trials diverse feasible design strategies therapeutics.

Language: Английский

Citations

3